Keytruda is the name for the immunotherapeutic drug pembrolizumab and was recently approved by the FDA to treat patients of high-risk early-stage triple negative breast cancer. Immunotherapy drugs are those that use the immune system to fight disease. Adult patient candidates with TNBC for this …